Share Price and Basic Stock Data
Last Updated: November 12, 2025, 10:49 pm
| PEG Ratio | -0.56 |
|---|
Analyst Insight & Comprehensive Analysis
Business Overview and Revenue Trends
Ambalal Sarabhai Enterprises Ltd operates in the pharmaceuticals sector, with its current market capitalization standing at ₹245 Cr and a share price of ₹32.0. The company reported a total revenue of ₹170 Cr for the fiscal year ending March 2023, showing a decline from ₹197 Cr in March 2022. However, the revenue for the trailing twelve months (TTM) remains stable at ₹196 Cr. Quarterly sales figures reveal fluctuations, with the highest sales recorded at ₹54.35 Cr in March 2024 and the lowest at ₹35.36 Cr in December 2022. Despite these variations, the company has shown resilience, achieving sales of ₹44.70 Cr in September 2024 and ₹45.97 Cr in December 2024. The sales trajectory indicates that the company is gradually recovering from previous downturns, although it still faces challenges in maintaining consistent growth compared to previous years.
Profitability and Efficiency Metrics
Ambalal Sarabhai Enterprises reported an operating profit margin (OPM) of 3.62%, which is relatively low compared to industry norms. The company recorded an operating profit of ₹9 Cr for the fiscal year ending March 2025, indicating a slight improvement from ₹8 Cr in March 2023. Net profit for the same period stood at ₹5 Cr, a drop from ₹11 Cr in March 2023, reflecting ongoing challenges in cost management and pricing strategies. The company’s return on equity (ROE) was reported at 6.25%, which is below the typical sector average, suggesting that shareholder returns are not optimal. Furthermore, the interest coverage ratio (ICR) of 4.56x indicates that the company can comfortably meet its interest obligations, demonstrating a degree of financial stability, but it remains imperative for the firm to enhance its profitability metrics to align more closely with sector standards.
Balance Sheet Strength and Financial Ratios
The balance sheet of Ambalal Sarabhai Enterprises reveals total borrowings of ₹51 Cr against reserves of ₹63 Cr, indicating a manageable debt level relative to its equity. The total liabilities stood at ₹270 Cr, while total assets were reported at ₹270 Cr as well, reflecting a balanced position. The company’s debt-to-equity ratio is at 0.34, which is relatively low, suggesting conservative leverage. The book value per share has increased to ₹18.27, up from ₹17.09 in March 2023, indicating a gradual strengthening of the company’s net asset value. However, the current ratio of 0.98 implies a potential liquidity concern, as it is below the ideal benchmark of 1. Additionally, the cash conversion cycle (CCC) of -2 days indicates efficient working capital management, although the company must ensure it does not compromise liquidity in the pursuit of efficiency.
Shareholding Pattern and Investor Confidence
The shareholding pattern of Ambalal Sarabhai Enterprises shows that promoters hold 31.35% of the company, reflecting a stable ownership structure. The public holds a significant 68.32%, while foreign institutional investors (FIIs) and domestic institutional investors (DIIs) account for 0.34% and 0.00%, respectively. This distribution indicates a lack of institutional backing, which may affect investor confidence. The number of shareholders has declined from 1,79,404 in December 2022 to 1,70,015 in March 2025, suggesting a loss of interest among retail investors. Despite this, the steady promoter stake could instill some confidence in the company’s governance. However, the absence of institutional investment might deter potential investors looking for stability and support from larger financial entities.
Outlook, Risks, and Final Insight
Ambalal Sarabhai Enterprises faces a mixed outlook characterized by both opportunities and challenges. One strength lies in its efficient working capital management, as evidenced by a negative cash conversion cycle, which can enhance liquidity if managed well. However, the company must address its low profitability metrics, which are significantly below industry standards, to improve investor sentiment and attract institutional investment. Risks include the company’s reliance on a fluctuating sales pattern and the absence of institutional backing, which could hinder growth prospects. If Ambalal Sarabhai can stabilize its revenue streams and enhance profitability, it could potentially improve its market position. Conversely, continued poor performance may lead to further declines in shareholder confidence and market valuation, impacting its future growth trajectory.
Source: Getaka Fundamental Analysis | Generated using proprietary financial data.
Competitors of Ambalal Sarabhai Enterprises Ltd
| Stock Name ⇩ | Market Cap ⇩ | Current Price ⇩ | High / Low ⇩ | Stock P/E ⇩ | Book Value ⇩ | Dividend Yield ⇩ | ROCE ⇩ | ROE ⇩ | Face Value ⇩ |
|---|---|---|---|---|---|---|---|---|---|
| Lactose (India) Ltd | 135 Cr. | 107 | 247/84.3 | 30.7 | 46.7 | 0.00 % | 12.9 % | 9.69 % | 10.0 |
| MPS Pharmaa Ltd | 3.52 Cr. | 1.84 | 4.33/1.82 | 0.57 | 0.00 % | 9.79 % | 59.0 % | 10.0 | |
| Gujarat Themis Biosyn Ltd | 4,901 Cr. | 450 | 479/192 | 102 | 24.3 | 0.15 % | 27.3 % | 21.7 % | 1.00 |
| Gujarat Terce Laboratories Ltd | 32.7 Cr. | 44.0 | 92.2/37.2 | 10.6 | 0.00 % | 41.4 % | 14.6 % | 10.0 | |
| Gujarat Inject (Kerala) Ltd | 38.0 Cr. | 26.0 | 29.1/17.0 | 39.6 | 6.83 | 0.00 % | 13.5 % | 11.0 % | 10.0 |
| Industry Average | 20,221.27 Cr | 1,192.93 | 53.76 | 199.56 | 0.34% | 16.24% | 14.95% | 6.10 |
Quarterly Result
| Metric | Jun 2022 | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 43.65 | 46.84 | 35.36 | 44.44 | 36.10 | 40.01 | 43.11 | 54.35 | 40.70 | 44.70 | 45.97 | 64.81 | 40.34 |
| Expenses | 42.91 | 46.11 | 33.79 | 41.09 | 40.07 | 39.00 | 40.58 | 49.70 | 40.23 | 42.16 | 46.67 | 59.51 | 38.88 |
| Operating Profit | 0.74 | 0.73 | 1.57 | 3.35 | -3.97 | 1.01 | 2.53 | 4.65 | 0.47 | 2.54 | -0.70 | 5.30 | 1.46 |
| OPM % | 1.70% | 1.56% | 4.44% | 7.54% | -11.00% | 2.52% | 5.87% | 8.56% | 1.15% | 5.68% | -1.52% | 8.18% | 3.62% |
| Other Income | 2.69 | 2.38 | 3.06 | 5.71 | 1.37 | 2.85 | 1.63 | 4.79 | 2.30 | 2.80 | 5.76 | -5.37 | 8.36 |
| Interest | 0.43 | 0.45 | 0.56 | 0.99 | 0.95 | 0.92 | 0.99 | 0.90 | 0.95 | 1.22 | 1.14 | 0.96 | 1.01 |
| Depreciation | 0.60 | 0.62 | 0.61 | 0.92 | 1.05 | 1.14 | 1.13 | 0.25 | 0.98 | 1.01 | 0.99 | 1.02 | 0.88 |
| Profit before tax | 2.40 | 2.04 | 3.46 | 7.15 | -4.60 | 1.80 | 2.04 | 8.29 | 0.84 | 3.11 | 2.93 | -2.05 | 7.93 |
| Tax % | 34.17% | 50.00% | 12.72% | 20.14% | 5.87% | 40.00% | 34.31% | -8.69% | 59.52% | 15.76% | 23.89% | -86.83% | -3.66% |
| Net Profit | 1.58 | 1.02 | 3.01 | 5.71 | -4.87 | 1.08 | 1.33 | 9.02 | 0.35 | 2.62 | 2.23 | -0.27 | 8.22 |
| EPS in Rs | 0.21 | 0.13 | 0.39 | 0.75 | -0.64 | 0.14 | 0.17 | 1.18 | 0.05 | 0.34 | 0.29 | -0.04 | 1.07 |
Last Updated: August 19, 2025, 11:55 pm
Below is a detailed analysis of the quarterly data for Ambalal Sarabhai Enterprises Ltd based on the most recent figures (Jun 2025) and their trends compared to the previous period:
- For Sales, as of Jun 2025, the value is 40.34 Cr.. The value appears to be declining and may need further review. It has decreased from 64.81 Cr. (Mar 2025) to 40.34 Cr., marking a decrease of 24.47 Cr..
- For Expenses, as of Jun 2025, the value is 38.88 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 59.51 Cr. (Mar 2025) to 38.88 Cr., marking a decrease of 20.63 Cr..
- For Operating Profit, as of Jun 2025, the value is 1.46 Cr.. The value appears to be declining and may need further review. It has decreased from 5.30 Cr. (Mar 2025) to 1.46 Cr., marking a decrease of 3.84 Cr..
- For OPM %, as of Jun 2025, the value is 3.62%. The value appears to be declining and may need further review. It has decreased from 8.18% (Mar 2025) to 3.62%, marking a decrease of 4.56%.
- For Other Income, as of Jun 2025, the value is 8.36 Cr.. The value appears strong and on an upward trend. It has increased from -5.37 Cr. (Mar 2025) to 8.36 Cr., marking an increase of 13.73 Cr..
- For Interest, as of Jun 2025, the value is 1.01 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 0.96 Cr. (Mar 2025) to 1.01 Cr., marking an increase of 0.05 Cr..
- For Depreciation, as of Jun 2025, the value is 0.88 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 1.02 Cr. (Mar 2025) to 0.88 Cr., marking a decrease of 0.14 Cr..
- For Profit before tax, as of Jun 2025, the value is 7.93 Cr.. The value appears strong and on an upward trend. It has increased from -2.05 Cr. (Mar 2025) to 7.93 Cr., marking an increase of 9.98 Cr..
- For Tax %, as of Jun 2025, the value is -3.66%. The value appears to be increasing, which may not be favorable. It has increased from -86.83% (Mar 2025) to -3.66%, marking an increase of 83.17%.
- For Net Profit, as of Jun 2025, the value is 8.22 Cr.. The value appears strong and on an upward trend. It has increased from -0.27 Cr. (Mar 2025) to 8.22 Cr., marking an increase of 8.49 Cr..
- For EPS in Rs, as of Jun 2025, the value is 1.07. The value appears strong and on an upward trend. It has increased from -0.04 (Mar 2025) to 1.07, marking an increase of 1.11.
Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.
Profit & Loss - Annual Report
Last Updated: October 15, 2025, 3:59 am
| Metric | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 105 | 124 | 132 | 134 | 125 | 150 | 133 | 163 | 197 | 170 | 173 | 196 | 196 |
| Expenses | 112 | 129 | 145 | 137 | 137 | 144 | 136 | 165 | 171 | 162 | 167 | 187 | 187 |
| Operating Profit | -7 | -4 | -13 | -3 | -12 | 6 | -3 | -2 | 25 | 8 | 6 | 9 | 9 |
| OPM % | -7% | -3% | -10% | -2% | -9% | 4% | -2% | -1% | 13% | 5% | 3% | 5% | 4% |
| Other Income | 2 | 13 | 95 | -2 | 25 | 8 | 24 | 40 | 33 | 12 | 10 | 5 | 12 |
| Interest | 11 | 10 | 4 | 5 | 3 | 3 | 4 | 3 | 2 | 3 | 6 | 5 | 4 |
| Depreciation | 3 | 5 | 17 | 4 | 2 | 2 | 3 | 2 | 2 | 3 | 4 | 4 | 4 |
| Profit before tax | -20 | -6 | 62 | -14 | 8 | 8 | 15 | 33 | 54 | 15 | 7 | 5 | 12 |
| Tax % | 3% | 13% | 22% | 34% | 84% | 48% | 6% | 10% | 13% | 25% | 15% | -2% | |
| Net Profit | -20 | -7 | 48 | -18 | 1 | 4 | 14 | 29 | 47 | 11 | 6 | 5 | 13 |
| EPS in Rs | -2.64 | -0.87 | 6.28 | -2.38 | 0.17 | 0.55 | 1.83 | 3.83 | 6.16 | 1.49 | 0.74 | 0.64 | 1.66 |
| Dividend Payout % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
YoY Net Profit Growth
| Year | 2014-2015 | 2015-2016 | 2016-2017 | 2017-2018 | 2018-2019 | 2019-2020 | 2020-2021 | 2021-2022 | 2022-2023 | 2023-2024 | 2024-2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| YoY Net Profit Growth (%) | 65.00% | 785.71% | -137.50% | 105.56% | 300.00% | 250.00% | 107.14% | 62.07% | -76.60% | -45.45% | -16.67% |
| Change in YoY Net Profit Growth (%) | 0.00% | 720.71% | -923.21% | 243.06% | 194.44% | -50.00% | -142.86% | -45.07% | -138.66% | 31.14% | 28.79% |
Ambalal Sarabhai Enterprises Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 11 years from 2014-2015 to 2024-2025.
Growth
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 5% |
| 5 Years: | 8% |
| 3 Years: | 0% |
| TTM: | 10% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 10% |
| 5 Years: | -9% |
| 3 Years: | -37% |
| TTM: | 60% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 15% |
| 5 Years: | 7% |
| 3 Years: | 1% |
| 1 Year: | -51% |
| Return on Equity | |
|---|---|
| 10 Years: | 6% |
| 5 Years: | 13% |
| 3 Years: | 7% |
| Last Year: | 6% |
Last Updated: September 5, 2025, 2:16 pm
No data available for the Balance Sheet data table.
Cash Flow - No data available for this post.
Financial Efficiency Indicators
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 95 | 74 | 83 | 79 | 100 | 84 | 79 | 87 | 52 | 59 | 55 | 82 |
| Inventory Days | 95 | 86 | 72 | 66 | 75 | 61 | 76 | 58 | 48 | 62 | 58 | 75 |
| Days Payable | 178 | 139 | 135 | 138 | 207 | 191 | 184 | 184 | 151 | 131 | 133 | 158 |
| Cash Conversion Cycle | 12 | 22 | 20 | 6 | -32 | -46 | -29 | -39 | -50 | -10 | -19 | -2 |
| Working Capital Days | -347 | -318 | -156 | -185 | -187 | -190 | -140 | -88 | -25 | -43 | -35 | -25 |
| ROCE % | -16% | -19% | -44% | -1% | -5% | 16% | 25% | 18% | 34% | 11% | 7% | 9% |
This stock is not held by any mutual fund.
Key Financial Ratios
| Month | Mar 25 | Mar 24 | Mar 23 | Mar 22 | Mar 21 |
|---|---|---|---|---|---|
| FaceValue | 10.00 | 10.00 | 10.00 | 10.00 | 10.00 |
| Basic EPS (Rs.) | 0.64 | 0.74 | 1.45 | 6.16 | 3.83 |
| Diluted EPS (Rs.) | 0.64 | 0.74 | 1.45 | 6.16 | 3.83 |
| Cash EPS (Rs.) | 1.08 | 1.56 | 1.94 | 5.63 | 2.96 |
| Book Value[Excl.RevalReserv]/Share (Rs.) | 18.27 | 17.90 | 17.09 | 15.64 | 9.64 |
| Book Value[Incl.RevalReserv]/Share (Rs.) | 18.27 | 17.90 | 17.09 | 15.64 | 9.64 |
| Revenue From Operations / Share (Rs.) | 25.60 | 22.65 | 22.22 | 25.67 | 21.35 |
| PBDIT / Share (Rs.) | 2.54 | 2.18 | 2.75 | 8.73 | 3.76 |
| PBIT / Share (Rs.) | 2.02 | 1.71 | 2.39 | 8.43 | 3.44 |
| PBT / Share (Rs.) | 0.54 | 1.22 | 2.07 | 6.23 | 3.06 |
| Net Profit / Share (Rs.) | 0.56 | 1.10 | 1.58 | 5.32 | 2.64 |
| NP After MI And SOA / Share (Rs.) | 0.64 | 0.74 | 1.45 | 6.16 | 3.83 |
| PBDIT Margin (%) | 9.92 | 9.61 | 12.36 | 34.00 | 17.59 |
| PBIT Margin (%) | 7.87 | 7.55 | 10.74 | 32.82 | 16.11 |
| PBT Margin (%) | 2.13 | 5.39 | 9.31 | 24.28 | 14.31 |
| Net Profit Margin (%) | 2.18 | 4.83 | 7.13 | 20.73 | 12.36 |
| NP After MI And SOA Margin (%) | 2.51 | 3.27 | 6.51 | 23.99 | 17.93 |
| Return on Networth / Equity (%) | 3.52 | 4.14 | 8.47 | 39.39 | 39.72 |
| Return on Capital Employeed (%) | 10.33 | 8.86 | 12.15 | 51.65 | 32.36 |
| Return On Assets (%) | 1.82 | 2.27 | 4.51 | 20.48 | 13.97 |
| Long Term Debt / Equity (X) | 0.05 | 0.06 | 0.13 | 0.02 | 0.07 |
| Total Debt / Equity (X) | 0.34 | 0.32 | 0.30 | 0.21 | 0.35 |
| Asset Turnover Ratio (%) | 0.75 | 0.69 | 0.71 | 0.00 | 0.00 |
| Current Ratio (X) | 0.98 | 1.16 | 1.23 | 1.14 | 0.93 |
| Quick Ratio (X) | 0.78 | 1.00 | 1.04 | 0.99 | 0.81 |
| Inventory Turnover Ratio (X) | 9.81 | 0.90 | 0.80 | 0.00 | 0.00 |
| Interest Coverage Ratio (X) | 4.56 | 4.44 | 8.64 | 39.34 | 9.76 |
| Interest Coverage Ratio (Post Tax) (X) | 3.65 | 3.23 | 5.98 | 33.88 | 7.86 |
| Enterprise Value (Cr.) | 305.67 | 360.72 | 169.24 | 264.81 | 129.80 |
| EV / Net Operating Revenue (X) | 1.56 | 2.08 | 0.99 | 1.35 | 0.79 |
| EV / EBITDA (X) | 15.70 | 21.61 | 8.04 | 3.96 | 4.51 |
| MarketCap / Net Operating Revenue (X) | 1.37 | 2.01 | 0.92 | 1.36 | 0.82 |
| Price / BV (X) | 1.92 | 2.54 | 1.20 | 2.23 | 1.83 |
| Price / Net Operating Revenue (X) | 1.37 | 2.01 | 0.92 | 1.36 | 0.82 |
| EarningsYield | 0.01 | 0.01 | 0.07 | 0.17 | 0.21 |
After reviewing the key financial ratios for Ambalal Sarabhai Enterprises Ltd, here is a detailed analysis based on the latest available data and recent trends:
- For FaceValue, as of Mar 25, the value is 10.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 10.00.
- For Basic EPS (Rs.), as of Mar 25, the value is 0.64. This value is below the healthy minimum of 5. It has decreased from 0.74 (Mar 24) to 0.64, marking a decrease of 0.10.
- For Diluted EPS (Rs.), as of Mar 25, the value is 0.64. This value is below the healthy minimum of 5. It has decreased from 0.74 (Mar 24) to 0.64, marking a decrease of 0.10.
- For Cash EPS (Rs.), as of Mar 25, the value is 1.08. This value is below the healthy minimum of 3. It has decreased from 1.56 (Mar 24) to 1.08, marking a decrease of 0.48.
- For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 18.27. It has increased from 17.90 (Mar 24) to 18.27, marking an increase of 0.37.
- For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 18.27. It has increased from 17.90 (Mar 24) to 18.27, marking an increase of 0.37.
- For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 25.60. It has increased from 22.65 (Mar 24) to 25.60, marking an increase of 2.95.
- For PBDIT / Share (Rs.), as of Mar 25, the value is 2.54. This value is within the healthy range. It has increased from 2.18 (Mar 24) to 2.54, marking an increase of 0.36.
- For PBIT / Share (Rs.), as of Mar 25, the value is 2.02. This value is within the healthy range. It has increased from 1.71 (Mar 24) to 2.02, marking an increase of 0.31.
- For PBT / Share (Rs.), as of Mar 25, the value is 0.54. This value is within the healthy range. It has decreased from 1.22 (Mar 24) to 0.54, marking a decrease of 0.68.
- For Net Profit / Share (Rs.), as of Mar 25, the value is 0.56. This value is below the healthy minimum of 2. It has decreased from 1.10 (Mar 24) to 0.56, marking a decrease of 0.54.
- For NP After MI And SOA / Share (Rs.), as of Mar 25, the value is 0.64. This value is below the healthy minimum of 2. It has decreased from 0.74 (Mar 24) to 0.64, marking a decrease of 0.10.
- For PBDIT Margin (%), as of Mar 25, the value is 9.92. This value is below the healthy minimum of 10. It has increased from 9.61 (Mar 24) to 9.92, marking an increase of 0.31.
- For PBIT Margin (%), as of Mar 25, the value is 7.87. This value is below the healthy minimum of 10. It has increased from 7.55 (Mar 24) to 7.87, marking an increase of 0.32.
- For PBT Margin (%), as of Mar 25, the value is 2.13. This value is below the healthy minimum of 10. It has decreased from 5.39 (Mar 24) to 2.13, marking a decrease of 3.26.
- For Net Profit Margin (%), as of Mar 25, the value is 2.18. This value is below the healthy minimum of 5. It has decreased from 4.83 (Mar 24) to 2.18, marking a decrease of 2.65.
- For NP After MI And SOA Margin (%), as of Mar 25, the value is 2.51. This value is below the healthy minimum of 8. It has decreased from 3.27 (Mar 24) to 2.51, marking a decrease of 0.76.
- For Return on Networth / Equity (%), as of Mar 25, the value is 3.52. This value is below the healthy minimum of 15. It has decreased from 4.14 (Mar 24) to 3.52, marking a decrease of 0.62.
- For Return on Capital Employeed (%), as of Mar 25, the value is 10.33. This value is within the healthy range. It has increased from 8.86 (Mar 24) to 10.33, marking an increase of 1.47.
- For Return On Assets (%), as of Mar 25, the value is 1.82. This value is below the healthy minimum of 5. It has decreased from 2.27 (Mar 24) to 1.82, marking a decrease of 0.45.
- For Long Term Debt / Equity (X), as of Mar 25, the value is 0.05. This value is below the healthy minimum of 0.2. It has decreased from 0.06 (Mar 24) to 0.05, marking a decrease of 0.01.
- For Total Debt / Equity (X), as of Mar 25, the value is 0.34. This value is within the healthy range. It has increased from 0.32 (Mar 24) to 0.34, marking an increase of 0.02.
- For Asset Turnover Ratio (%), as of Mar 25, the value is 0.75. It has increased from 0.69 (Mar 24) to 0.75, marking an increase of 0.06.
- For Current Ratio (X), as of Mar 25, the value is 0.98. This value is below the healthy minimum of 1.5. It has decreased from 1.16 (Mar 24) to 0.98, marking a decrease of 0.18.
- For Quick Ratio (X), as of Mar 25, the value is 0.78. This value is below the healthy minimum of 1. It has decreased from 1.00 (Mar 24) to 0.78, marking a decrease of 0.22.
- For Inventory Turnover Ratio (X), as of Mar 25, the value is 9.81. This value exceeds the healthy maximum of 8. It has increased from 0.90 (Mar 24) to 9.81, marking an increase of 8.91.
- For Interest Coverage Ratio (X), as of Mar 25, the value is 4.56. This value is within the healthy range. It has increased from 4.44 (Mar 24) to 4.56, marking an increase of 0.12.
- For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is 3.65. This value is within the healthy range. It has increased from 3.23 (Mar 24) to 3.65, marking an increase of 0.42.
- For Enterprise Value (Cr.), as of Mar 25, the value is 305.67. It has decreased from 360.72 (Mar 24) to 305.67, marking a decrease of 55.05.
- For EV / Net Operating Revenue (X), as of Mar 25, the value is 1.56. This value is within the healthy range. It has decreased from 2.08 (Mar 24) to 1.56, marking a decrease of 0.52.
- For EV / EBITDA (X), as of Mar 25, the value is 15.70. This value exceeds the healthy maximum of 15. It has decreased from 21.61 (Mar 24) to 15.70, marking a decrease of 5.91.
- For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 1.37. This value is within the healthy range. It has decreased from 2.01 (Mar 24) to 1.37, marking a decrease of 0.64.
- For Price / BV (X), as of Mar 25, the value is 1.92. This value is within the healthy range. It has decreased from 2.54 (Mar 24) to 1.92, marking a decrease of 0.62.
- For Price / Net Operating Revenue (X), as of Mar 25, the value is 1.37. This value is within the healthy range. It has decreased from 2.01 (Mar 24) to 1.37, marking a decrease of 0.64.
- For EarningsYield, as of Mar 25, the value is 0.01. This value is below the healthy minimum of 5. There is no change compared to the previous period (Mar 24) which recorded 0.01.
Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.
Strength and Weakness
Unable to fetch valid data for stock valuation.Stock Analysis
- Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Ambalal Sarabhai Enterprises Ltd:
- Net Profit Margin: 2.18%
- Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
- ROCE: 10.33% (Industry Average ROCE: 16.24%)
- ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
- ROE%: 3.52% (Industry Average ROE: 14.95%)
- ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
- Interest Coverage Ratio (Post Tax): 3.65
- Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
- Quick Ratio: 0.78
- Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
- Stock P/E: 13 (Industry average Stock P/E: 53.76)
- Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
- Total Debt / Equity: 0.34
- Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
Stock Rating: - Net Profit Margin: 2.18%
About the Company - Qualitative Analysis
| INDUSTRY | ADDRESS | CONTACT |
|---|---|---|
| Pharmaceuticals | Shanti Sadan, Mirzapur Road, Ahmedabad Gujarat 380001 | dsejpal@ase.life http://www.ase.life |
| Management | |
|---|---|
| Name | Position Held |
| Mr. Kartikeya V Sarabhai | Executive Chairman |
| Mr. Mohal K Sarabhai | Managing Director |
| Ms. Chaula M Shastri | Whole Time Director |
| Dr. Pushpa Robin | Independent Director |
| Mr. Mayur Swadia | Independent Director |
| Mr. Satyen Dave | Independent Director |
| Mr. Brijesh Khandelwal | Independent Director |
| Mr. Govindprasad Namdeo | Independent Director |
| Mr. Ajay Mayor | Nominee Director |
| Mr. Bharatendu Jani | Nominee Director |